Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
231. |
ECCT/24/03/04 | MK8591A-053 Trial A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county) 2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county) 3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county) |
19-06-2024 |
View |
232. |
ECCT/22/03/02 | MOVe AHEAD STUDY A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19 |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI RCTP KISUMU |
31-05-2022 |
View |
233. |
ECCT/22/06/02 | Mitapivat - AG348-C-020 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. |
Principal Investigator(s) 1. Lucas Otieno Tina 2. Bernhards Ragama Ogutu 3. Prof Jessie N Githanga 4. Videlis N Nduba 5. Janet N/A Oyieko 6. Allan Godfrey Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Strathmore University Medical Centre (Nairobi City county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
06-09-2022 |
View |
234. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
07-10-2025 |
View |
235. |
ECCT/21/06/03 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. PROF.ELIZABETH ANNE BUKUSI 2. MARICIANAH A ONONO Site(s) in Kenya 1. Kenya Medical Research Institute (KEMRI) Center for Microbiology Research - Research Care and Training Program (KEMRI CMRRCTP) (Kisumu county) 2. KEMRI CCRButere County Hospital Site (Kakamega county) 3. Aga Khan University Hospital (Nairobi City county) 4. Kenya Medical Research Institute CGHR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county) 7. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county) 8. Ganjoni Clinic (Mombasa county) 9. KEMRI-UAMRD-A/K, Kombewa Clinical Research Cente (Kisumu county) 10. KEMRI/Walter Reed Project Research Center (Kericho county) |
02-08-2021 |
View |
236. |
ECCT/21/06/12 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI/Walter Reed Project Research Center (Kericho county) 3. Kenya Medical Research Institute (Kisumu county) 4. Ganjoni Clinic (Mombasa county) 5. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county) 6. Kenya Medical Research Institute (Nairobi City county) 7. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 8. Aga Khan University Hospital (Nairobi City county) 9. KEMRI CCR-Butere County Hospital Site (Bung\'oma county) |
16-08-2021 |
View |
237. |
21/06/16 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya 1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county) 2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county) 3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county) 4. Partners in Health Research and Development, Thika (Kiambu county) 5. KARGENO RESEARCH AND POLICY HUB (Kisumu county) 6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county) 7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county) 9. Aga Khan University Hospital (Nairobi City county) 10. KEMRI CCR-Butere County Hospital Site (Kakamega county) |
02-08-2021 |
View |
238. |
ECCT/26/06/02 | HibiscusJr A global phase 3 Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of etavopivat in children with Sickle Cell Disease. |
Principal Investigator(s) 1. Dr. Sharon Mokeira Ocharo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) |
23-10-2026 |
View |
239. |
ECCT/22/01/01 | ASTEFANIA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
21-07-2022 |
View |
240. |
ECCT/19/07/01 | IMPROVE-2 chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2). |
Principal Investigator(s) 1. Hellen Cherono Barsosio 2. Simon Kariuki Site(s) in Kenya 1. Ahero Sub-County Hospital (Kisumu county) 2. Rabuor Sub-County Hospital (Kisumu county) 3. Akala Sub-County Hospital (Siaya county) |
03-10-2019 |
View |